Skip to main navigation Skip to search Skip to main content

National institutes of health pathways to prevention workshop: Research gaps for long-term drug therapies for osteoporotic fracture prevention

  • Albert Siu
  • , Heather Allore
  • , Darryl Brown
  • , Susan T. Charles
  • , Matthew Lohman

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

On 30 and 31 October 2018, the National Institutes of Health convened the Pathways to Prevention (P2P) Workshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention to assess the available evidence on long-term (>3 years) use of drug therapies to prevent osteoporotic fractures and identify research gaps and needs for advancing the field. The workshop was cosponsored by the NIH Office of Disease Prevention (ODP), National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute on Aging. A multidisciplinary working group developed the agenda, and an Evidencebased Practice Center prepared an evidence report through a contract with the Agency for Healthcare Research and Quality to facilitate the discussion. During the 1.5-day workshop, invited experts discussed the body of evidence and attendees had the opportunity to comment during open discussions. After data from the evidence report, expert presentations, and public comments were weighed, an unbiased independent panel prepared a draft report that was posted on the ODP Web site for 5 weeks for public comment. This final report summarizes the panel's findings and recommendations. Current gaps in knowledge are highlighted, and a set of recommendations for new, strengthened research to better inform the long-term use of osteoporotic drug therapies is delineated.

Original languageEnglish
Pages (from-to)51-57
Number of pages7
JournalAnnals of Internal Medicine
Volume171
Issue number1
DOIs
StatePublished - 2019

Fingerprint

Dive into the research topics of 'National institutes of health pathways to prevention workshop: Research gaps for long-term drug therapies for osteoporotic fracture prevention'. Together they form a unique fingerprint.

Cite this